Business
River Point Farms adds to onion portfolio
Business
Pfizer (PFE) Stock Holds Near $27.14 After Q4 2025 Beat, Reaffirms 2026 Guidance Amid COVID Decline
Pfizer Inc.’s stock traded modestly higher near $27.14 in late February 2026, closing at $27.14 on February 24 after a 0.30% gain, as the pharmaceutical giant builds on solid fourth-quarter and full-year 2025 results that beat expectations while reaffirming its 2026 outlook despite anticipated revenue pressures from declining COVID-19 products and patent expirations.

As of February 24, 2026, Pfizer (NYSE: PFE) traded in a session range of $27.08 to $27.42 with volume of approximately 34.7 million shares. The shares have risen about 6-7% over the past month and remain near the upper end of their 52-week range from around $20.92 to $27.94. Market capitalization stands near $153-154 billion, reflecting cautious optimism amid a transitional period for the company.
The performance follows Pfizer’s fourth-quarter and full-year 2025 earnings released February 3, 2026. The company reported full-year revenue of $62.6 billion, down 2% operationally year-over-year, but non-COVID portfolio revenues grew 6% operationally. Fourth-quarter revenue reached $17.6 billion, down 3% operationally, while adjusted diluted EPS for Q4 hit $0.66, beating consensus estimates of around $0.56-$0.57 by $0.09-$0.10. Full-year adjusted diluted EPS came in at $3.22, above prior guidance ranges.
Excluding contributions from Comirnaty and Paxlovid, the company delivered strong underlying growth driven by oncology, rare disease, and other key franchises. Management highlighted disciplined execution, cost savings, and margin expansion, with adjusted gross margin reaching 76% for the year. Free cash flow remained robust, supporting $9.8 billion in dividend payments and investments in R&D and business development, including the Metsera acquisition and other deals adding to the obesity and immunology pipeline.
Pfizer reaffirmed its full-year 2026 guidance, projecting revenue of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. The outlook incorporates approximately $5 billion in expected COVID-19 product revenues and a roughly $1.5 billion negative impact from products facing loss of exclusivity (LOE). Non-COVID and non-LOE revenues are anticipated to grow about 4% operationally at the midpoint. The guidance also reflects productivity savings of $7.2 billion targeted by end-2026, manufacturing program savings of $1.5 billion by 2027, and continued investment in approximately 20 key pivotal study starts planned for 2026.
CEO Albert Bourla described 2025 as “a very good year” marked by strong execution, while noting 2026 as a catalyst-rich period with pivotal trials advancing, including in obesity (ultra-long-acting assets from Metsera) and oncology (PD-1 x VEGF bispecific from 3SBio). The company emphasized its late-stage pipeline strength and strategic focus on high-value therapeutic areas to offset headwinds.
Analysts remain mixed but generally constructive on the long-term outlook. Consensus among 22 analysts rates PFE a Hold, with average 12-month price targets around $27.70—implying modest upside of about 2% from recent levels. Targets range from lows near $23-$24 to highs of $35, reflecting divergence on pipeline execution and revenue risks. Some firms maintain Buy ratings citing undervaluation and dividend appeal (yield around 6.3-6.4%), while others express caution over patent cliffs and modest growth prospects.
The next earnings report, for first-quarter 2026, is expected in late April or early May 2026. Investors will scrutinize updates on non-COVID growth, pipeline milestones, cost discipline, and any refinements to full-year guidance amid evolving macro and policy dynamics.
Pfizer continues navigating a post-COVID landscape with a diversified portfolio, robust cash flow, and aggressive R&D investment. While near-term revenue faces headwinds from declining pandemic products and LOE impacts, the company’s scale, pipeline advancements, and shareholder returns position it for potential recovery as new therapies launch in coming years. With shares trading at attractive multiples relative to historical averages and peers, Pfizer remains a core holding for income-focused investors seeking stability in healthcare.
Business
Trump says admin will lower housing costs, keep home values up
The Corcoran Group broker, Noble Black, joins Varney & Co. to discuss homebuilder confidence, mortgage rates and Congress actions to address the housing crisis.
President Donald Trump said his administration plans to make housing more affordable for new homebuyers while keeping home values high for existing homeowners.
Trump delivered his State of the Union address to a joint session of Congress on Tuesday night and touted the lower cost of new mortgages since he took office in January 2025.
“Mortgage rates are the lowest in four years and falling fast, and the annual cost of a typical new mortgage is down almost $5,000 just since I took office. One year,” Trump said.
“Low interest rates will solve the Biden-created housing problem while at the same time protecting the values of those people who already own a house that really feel rich for the first time in their lives. We want to protect those values; we want to keep those values up. We are going to do both. And we are going to keep it that way,” the president added.
FHFA CHIEF SAYS TRUMP DEPLOYED $200B TO SLASH MORTGAGE RATES, CLAIMS IMPACT WAS IMMEDIATE

President Donald Trump touted the decline in mortgage rates since he took office during his State of the Union address. (Kent Nishimura/Reuters)
Data from Freddie Mac shows that the average rate on a 30-year fixed mortgage declined from 7.04% in January 2025, when Trump began his second term, to the current 6.01%.
While lower interest rates can help with the affordability of mortgages taken out by new homeowners, they have an inverse relationship with home prices, as lower rates stimulate demand among prospective buyers, which pushes home values higher.
That dynamic can counteract the affordability improvements from lower mortgage rates by increasing the size of the mortgage, as both elements factor into the owner’s monthly payments.
Investors have noted that the most effective way to lower home prices would be to expand the supply of homes, though they cautioned that most of the laws and regulations are governed at the state and local level, which gives the federal government few options.
EFFORTS TO REIN IN WALL STREET LANDLORDS COULD PUSH US HOME PRICES UP, INVESTORS SAY

Investors say expanding the supply of homes is the best way to make homeownership more affordable for Americans. (Joshua Lott/Bloomberg via Getty Images)
Trump also discussed his plan to ban institutional investors from buying large numbers of homes, citing the experience of a State of the Union guest who he said was outbid for 20 homes by “gigantic investment firms that bypassed inspection. Paid all cash and turned those houses into rentals, stealing away her American dream.”
The president said that stories like those prompted his executive order banning large investment firms from buying homes and called on Congress to make the ban permanent, adding that, “We want homes for people, not for corporations.”
Trump’s order directs federal regulators to promote home sales to individuals and to issue guidance preventing federal programs from facilitating single-family home sales to Wall Street investors. The order also mandates antitrust scrutiny of institutional home purchases and calls on Congress to codify the changes into law.
TRUMP MOVES TO BLOCK WALL STREET FROM BUYING SINGLE-FAMILY HOMES IN SWEEPING NEW EXECUTIVE ORDER

Lower interest rates bring more buyers into the market, which can push home values higher. (Andrew Burton/Getty Images)
Jake Krimmel, senior economist at Realtor.com, said of the move that, “In particular, large institutional investors represent a relatively small share of the national housing stock, and because their activity is often highly localized, it remains an open question whether banning new purchases would meaningfully shift metro-level markets.”
National Association of Home Builders CEO Jim Tobin said that his organization has been engaged with the administration to push policies that could help lower the cost of building new homes, adding that “corporate investment in housing has been a driver of new home construction.”
Wall Street firms including Blackstone, American Homes 4 Rent and Progress Residential have bought thousands of homes since the 2008 financial crisis prompted a wave of foreclosures. Firms owned about 3% of all single-family rental homes by June 2022, government data showed.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Those firms dispute that their investments have stoked inflation in housing prices, with Blackstone noting it has been a net seller of homes for the last decade.
Reuters contributed to this report.
Business
Rocket Companies (RKT) Stock Rises to $17.71 Ahead of Q4 2025 Earnings, Analysts Watch for Mortgage Recovery
Rocket Companies Inc.’s stock climbed 3.63% to close at $17.71 on February 24, 2026, snapping a recent losing streak as investors positioned for the company’s fourth-quarter and full-year 2025 earnings report on February 26, with focus on mortgage origination trends, servicing growth from the Mr. Cooper acquisition, and progress toward profitability in a volatile interest rate environment.

As of February 24, 2026, Rocket Companies (NYSE: RKT) traded in a session range of $16.58 to $17.75 with volume exceeding 23.9 million shares. The shares have shown volatility year-to-date in 2026, down from early January levels near $20 but up significantly from 2025 lows around $10.94. Market capitalization stands around $37 billion, reflecting cautious optimism amid ongoing mortgage market challenges.
The February 24 gain followed analyst previews and options activity signaling potential volatility around earnings. Consensus estimates call for Q4 revenue of approximately $2.26 billion to $2.30 billion—up sharply from prior-year levels due to higher origination volumes—and EPS near $0.00 to $0.08, a modest improvement from losses in comparable periods. Full-year 2025 revenue is projected at $6.32 billion, with EPS around -$0.14.
The earnings mark a pivotal moment as Rocket integrates its pending acquisition of Mr. Cooper Group, expected to create the largest U.S. mortgage servicer with a combined servicing base nearing 10 million loans. The deal, announced in prior periods, aims to build a “flywheel” of origination, servicing, and technology to capture volume when rates decline. Analysts note that lower rates in 2026 could drive refinancing activity, benefiting Rocket’s platform.
Rocket’s Q3 2025 results, reported earlier, showed adjusted revenue of $1.78 billion, adjusted EBITDA of $349 million, and adjusted diluted EPS of $0.07, with strong client experience metrics and technology advantages highlighted. The company continues emphasizing its vertically integrated model, including Rocket Mortgage, Rocket Homes, and related services, to navigate a high-rate environment that has suppressed purchase and refinance demand.
Recent news includes a Super Bowl ad partnership with Redfin emphasizing neighborly homeownership, released February 6, 2026, and ongoing efforts to support small businesses in mortgage-related services. Institutional activity showed mixed moves, with Rhumbline Advisers increasing its stake by 68.2% in Q3 2025, adding shares worth about $4.11 million.
Analyst sentiment remains mixed. Consensus among covering firms leans Hold, with average 12-month price targets around $20.50 to $21.57—implying 15-22% upside from recent levels. Some firms express caution due to rate sensitivity and integration risks from Mr. Cooper, while others highlight potential for earnings recovery if mortgage volumes rebound. Options markets have priced in meaningful moves around the February 26 release, with elevated implied volatility and skewed positioning.
Rocket’s strategy focuses on technology and data advantages to enhance client experience and operational efficiency. The company anticipates 2026 as a recovery year for mortgage activity, with guidance updates expected on the earnings call at 4:30 p.m. ET on February 26. Positive commentary on origination growth, servicing scale, or cost controls could extend gains; any signs of prolonged weakness in housing might pressure shares further.
Rocket Companies, founded as Quicken Loans and rebranded, remains a leader in U.S. mortgage origination and servicing. Its platform approach and acquisition strategy position it to benefit from eventual rate relief and housing market stabilization. As earnings approach, investor attention will center on execution amid macro uncertainty and the path to consistent profitability.
Business
The future of coffee is cold

Nestle and J.M. Smucker see new paths to growth in cold coffee formats.
Business
Food prices projected to plateau

Grocery inflation slows as retail beef prices climb and egg prices retreat.
Business
Exclusive | Raine Group Hires Former Credit Suisse IPO Veteran
The Raine Group has hired initial public offering veteran Anthony Kontoleon as a partner as the merchant bank gears up for a blockbuster stretch of technology debuts and private-company fundraising, the firm told The Wall Street Journal.
The details
Raine works with big sports media, telecommunications and tech companies on their mergers and acquisitions and served as a financial adviser for the giant stock offering of chip designer Arm Holdings in 2023. Raine hopes to take the latter role on more.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Business
Fresenius Medical Care Shares Drop After Outlook Underwhelms
Fresenius Medical Care FME -0.10%decrease; red down pointing triangle shares fell after the German dialysis specialist forecast flattish revenue and adjusted earnings in the year ahead amid regulatory headwinds.
Shares in Fresenius Medical Care were down 5.9% in European midday trading Tuesday, having fallen around 10% earlier. The decline erased the stock’s gains since the start of 2026.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Business
Faisal Islam: Is Reeves right in saying we're turning a corner?
The Chancellor is trying to use this moment as a launching pad for a wider attempt to gee up consumer and business confidence.
Business
Slideshow: Formulating frozen food innovations

New product launches focus on healthier ingredients and global flavors.
Business
Heston Blumenthal’s restaurant empire under threat after HMRC winding-up petition
The future of The Fat Duck and other restaurants founded by Heston Blumenthal is in doubt after HM Revenue & Customs issued a winding-up petition against the chef’s parent company.
HMRC has moved against SL6 Ltd, which owns The Fat Duck in Bray, Berkshire, alongside the one-Michelin-starred The Hinds Head and several affiliated ventures. Around 130 staff are understood to be at risk should the petition proceed.
The action follows a further deterioration in the group’s finances. Accounts filed at Companies House show SL6 Ltd recorded a loss of £2.05m for the year to 2024, up from £1.39m the previous year, despite turnover of £8.9m.
Administrative expenses totalled £8.4m, including £2.3m in cost of sales, while staff costs rose to £4.07m, reflecting inflationary pressure and higher wage bills.
The company’s accounts reveal total debts of £2.7m, including £1.67m owed in taxation and social security and £5,417 in corporation tax. It also reported a bank overdraft of £806,091, more than the £697,605 held in cash, alongside several outstanding bank loans.
A strategic report signed by Ronald Lowenthal, who now controls SL6 Ltd after Blumenthal sold his stake in 2006, acknowledged a year of “tough economic conditions”, citing inflation across the supply chain, recruitment challenges and rising wage costs.
Lowenthal said the company had chosen not to pass the full burden of inflation on to customers, despite the impact on profitability. The Fat Duck’s signature 13-course tasting menu, “The Journey”, is currently priced at £350 per head.
Auditors Lawfords Consulting previously described the business as a “going concern”, noting management was seeking long-term funding to stabilise operations. However, HMRC’s decision to file a winding-up petition suggests negotiations may not have secured sufficient support.
A spokesperson for HMRC said it could not comment on individual cases but added that winding-up petitions are only filed after other recovery options have been exhausted.
The development comes at a difficult time for the UK hospitality sector, which has faced rising energy bills, food inflation and higher employment costs in recent years. Fine dining establishments have been particularly exposed to fluctuations in discretionary spending.
The timing is also notable given fresh political debate around the value of the hospitality sector. Comments this week from a senior government adviser suggesting Britain does not “need any more restaurants” have drawn criticism from industry figures already grappling with higher taxes and regulatory pressures.
Blumenthal, famed for inventive dishes such as snail porridge and “Sound of the Sea”, became one of Britain’s most recognisable chefs through The Fat Duck’s experimental cuisine and television appearances. The restaurant has long been regarded as a cornerstone of modern British gastronomy.
If the winding-up petition proceeds and the company cannot secure funding or reach a settlement with HMRC, the case could result in compulsory liquidation, placing one of Britain’s most celebrated culinary brands in jeopardy, however a spokesperson for SL6 Limited, has said: “This was an administrative oversight during our transition to a new accounting system, which we are working to resolve. Our restaurants are busier than ever, and there will be no impact on our operations. From our side, it is business as usual.”
-
Video6 days agoXRP News: XRP Just Entered a New Phase (Almost Nobody Noticed)
-
Politics4 days agoBaftas 2026: Awards Nominations, Presenters And Performers
-
Fashion5 days agoWeekend Open Thread: Boden – Corporette.com
-
Sports2 days agoWomen’s college basketball rankings: Iowa reenters top 10, Auriemma makes history
-
Politics2 days agoNick Reiner Enters Plea In Deaths Of Parents Rob And Michele
-
Sports7 days agoClearing the boundary, crossing into history: J&K end 67-year wait, enter maiden Ranji Trophy final | Cricket News
-
Crypto World2 days agoXRP price enters “dead zone” as Binance leverage hits lows
-
Business3 days agoMattel’s American Girl brand turns 40, dolls enter a new era
-
Business3 days agoLaw enforcement kills armed man seeking to enter Trump’s Mar-a-Lago resort, officials say
-
Entertainment7 days agoDolores Catania Blasts Rob Rausch For Turning On ‘Housewives’ On ‘Traitors’
-
Tech1 day agoUnsurprisingly, Apple's board gets what it wants in 2026 shareholder meeting
-
NewsBeat2 days ago‘Hourly’ method from gastroenterologist ‘helps reduce air travel bloating’
-
Tech3 days agoAnthropic-Backed Group Enters NY-12 AI PAC Fight
-
NewsBeat3 days agoArmed man killed after entering secure perimeter of Mar-a-Lago, Secret Service says
-
Politics3 days agoMaine has a long track record of electing moderates. Enter Graham Platner.
-
NewsBeat23 hours agoPolice latest as search for missing woman enters day nine
-
Crypto World23 hours agoEntering new markets without increasing payment costs
-
Sports2 days ago
2026 NFL mock draft: WRs fly off the board in first round entering combine week
-
Crypto World6 days ago83% of Altcoins Enter Bear Trend as Liquidity Crunch Tightens Grip on Crypto Market
-
Business1 day agoTrue Citrus debuts functional drink mix collection

